Article
CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors.
Nature cancer - 1 May 2025
Chen Feiyu, Li Haoyan, Wang Yin, Tang Ximing, Lin Kevin, Li Qidong, Meng Chenling, Shi Wei, Leo Javier, Liang Xin, Zhang Jie, Van Vivien, Mahmud Iqbal, Wei Bo, Lorenzi Philip L, Raso Maria G, Aparicio Ana, Lu Yue, Frigo Daniel E, Gan Boyi, Zhao Di
Abstract excerpt
Despite undergoing castration, most individuals with prostate cancer (PCa) experience progression to castration-resistant PCa (CRPC), in which the androgen receptor (AR) remains an important driver. Concurrent genetic alterations in SPOP and CHD1 define a unique subtype of PCa, but their interactions in tumor progression and therapy response remain unclear. Here, we provide genetic evidence supporting that CHD1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.